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Background: A pathway-based genotyping analysis suggested rs2078486 was a novel TP53 SNP, but very few studies
replicate this association. TP53 rs1042522 is the most commonly studied SNP, but very few studies examined its potential
interaction with environmental factors in relation to lung cancer risk. This study aims to examine associations between
two TP53 single-nucleotide polymorphisms (SNPs) (rs2078486, rs1042522), their potential interaction with environmental
factors and risk of lung cancer.
Methods: A case–control study was conducted in Taiyuan, China. Unconditional logistic regression was used to estimate
odds ratios (ORs) and 95% confidence intervals (95% CIs). Multiplicative and additive interactions between TP53 SNPs
and lifestyle factors were evaluated.
Results: Variant TP53 rs2078486 SNP was significantly associated with elevated lung cancer risk among smokers
(OR: 1.70, 95% CI: 1.08 - 2.67) and individuals with high indoor air pollution exposure (OR: 1.51, 95% CI: 1.00-2.30).
Significant or borderline significant multiplicative and additive interactions were found between TP53 rs2078486
polymorphism with smoking and indoor air pollution exposure. The variant genotype of TP53 SNP rs1042522
significantly increased lung cancer risk in the total population (OR: 1.57, 95% CI: 1.11-2.21), but there was no
evidence of heterogeneity among individuals with different lifestyle factors.
Conclusions: This study confirmed that TP53 rs2078486 SNP is potentially a novel TP53 SNP that may affect
lung cancer risk. Our study also suggested potential synergetic effects of TP53 rs2078486 SNP with smoking
and indoor air pollution exposure on lung cancer risk.
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Lung cancer is one of the most common cancers and is
a leading cause of cancer death in China. It was esti-
mated that by year 2025, more than one million Chinese
will be diagnosed with lung cancer per year [1]. Lung
cancer mortality increased 465% during the past 30 years
and now is the leading cancer death cause in China [2].
Smoking is regarded as the most important risk factor
for lung cancer, and indoor air pollution from cooking* Correspondence: linamu@buffalo.edu
†Equal contributors
1Department of Social and Preventive Medicine, School of Public Health and
Health Professions, The State University of New York (SUNY) at Buffalo, 273A
Farber Hall, Buffalo, New York 14214-8001, USA
Full list of author information is available at the end of the article
© 2013 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand heating is another potential risk factor in Chinese
population [3]. However, approximately one in ten life-
time smokers develop lung cancer, which implies a pos-
sible role for genetic susceptibility in the development of
lung cancer [4].
The TP53 tumor suppressor gene plays a critical role
in modulating transcription of genes that govern the
major defenses against tumor growth, including cell
cycle arrest, apoptosis, maintenance of genetic integrity,
inhibition of angiogenesis and cellular senescence [5].
The TP53 gene harbors high-frequency, functional
single-nucleotide polymorphisms (SNPs) which may
alter P53 protein function [6]. Several functional TP53
SNPs have been reported to be associated with riskhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancer [7-9].
TP53 rs2078486 SNP was recently identified to be as-
sociated with lung cancer risk in lifetime never smokers
in a pathway-based genotyping study which evaluated a
comprehensive panel of 11,737 SNPs in inflammatory-
pathway genes [10]. One case–control study conducted
among 611 lung cancer cases and 1040 controls in Los
Angeles found elevated lung cancer risk associated with
the variant genotype of TP53 rs2078486 SNP (doctoral
dissertation from Yi Ren Wang) [11]. However this asso-
ciation was not confirmed by another pooled genome-
wide association study [12]. In addition to lung cancer,
TP53 rs2078486 SNP has been also linked with risk of
ovarian cancer [13] and schizophrenia [14]. To our
knowledge, no case–control study has been conducted
in the Asian population to replicate the association of
TP53 rs2078486 SNP with lung cancer.
The most studied TP53 SNP rs1042522 is character-
ized by substitution of Arginine (Arg) by Proline (Pro) at
codon 72 (G12139C, Arg72Pro) and may noticeably
affect P53 function [15]. However, very few studies ex-
amined if there are interactions between Arg72Pro poly-
morphism and smoking or other lifestyle factors on lung
cancer risk.
A case–control study was conducted to examine the
associations of TP53 rs2078486 and rs1042522 SNPs
with lung cancer risk in a Chinese population and fur-




A case–control study was conducted between 2005 and
2007 in Taiyuan city, the capital of Shanxi province,
China. The original study population has been described
in detail previously [16]. Prior to the initiation of the
recruitment, IRB approvals were obtained from Fudan
University (IRB#04-10-0022) and UCLA (IRB#11-003153),
respectively. Lung cancer cases were enrolled from the
Shanxi tumor hospital, which admitted about 70% of the
cancer patients from the city. Eligible cases were newly
diagnosed lung cancer cases, 20 years of age or older,
lived in Taiyuan city for 10 years or more, in stable med-
ical condition and willing to participate. Controls were
randomly selected from 13 communities in Taiyuan city.
Eligible controls were 20 years of age or older, must have
lived in Taiyuan city for 10 years or more, and had no
history of cancer or any other serious chronic diseases. A
total of 399 lung cancer patients and 466 healthy controls
were recruited to participate in this study. Response rates
were 89% for eligible cases and 85% for eligible controls.
Written informed consent was obtained from all study
participants.Data collection
All cases and controls were interviewed by professional
staff to collect information on demographic factors, diet-
ary and cooking habits, active and passive smoking history,
alcohol drinking habits, tea drinking habits, residence and
housing history, occupational history and related expos-
ure, physical activities and disease history.
Blood sample collection and laboratory analysis of gene
polymorphisms
Blood samples were collected from 97.9% of cases and
98.9% of controls. Serum and blood clot were immediately
separated and all samples were stored in freezer at −80°C.
Genomic DNA was extracted using a modified phenol-
chloroform protocol. Genotyping was performed in the
Molecular Epidemiology Laboratory at Department of
Epidemiology, School of Public Health at UCLA. TP53
SNP genotyping was performed using Sequenom platform
(Sequenom, Inc., San Diego, CA). Polymerase chain reac-
tion (PCR) and extension primers were designed using
MassARRAY Assay Design 3.1 software (Sequenom, Inc.,
San Diego, CA). Genotyping procedures were performed
according to the manufacturer’s iPLEX Application Guide
(Sequenom Inc. SanDiego,CA). For quality control, we
included two negative controls (H2O) in each 96-well
plate. Around 4.5% of samples were selected for dupli-
cation and the concordance is 99.5%. We found no ob-
vious deviations from Hardy-Weinberg equilibrium for
both SNPs (rs2078486: χ2 = 0.19, P = 0.6629; rs1042522:
χ2 = 4.24, P = 0.0395) among control subjects. We did not
find strong linkage disequilibrium between the two
SNPs (D’ < 0.5) in the current study and this is con-
sistent with previous studies [17,18].
Definition of indoor air pollution index
An indoor air pollution index was created to integrate
the impacts from different types of cooking and heating
fuels, use of ventilator in kitchen, windows opening be-
haviors and secondhand smoke exposure at home on in-
door air pollution levels. For each component of this
index, a score of ‘0′ or ‘1′ represented low or high in-
door air pollution, respectively. A summarized score
lower than 2 was defined as low indoor air pollution ex-
posure and higher or equal to 2 was defined as high in-
door air pollution exposure [16].
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (95% CIs)
were estimated using unconditional logistic regression
models to evaluate the independent effects of the two
TP53 SNPs. We presented each of the associations in addi-
tive, dominant and recessive models, respectively. Potential
confounding factors adjusted in the multivariate models
included age, education level, annual personal income
Table 1 Basic characteristics of cases and controls in
Taiyuan lung cancer study
Variable Cases Controls P value
N (%) N (%)
Age
≤ 45 years 59 (14.8) 83 (17.8)
0.0725
45 – 55 yrs 96 (24.1) 139 (29.8)
55 – 65 yrs 111 (27.8) 116 (25.0)
> 65 yrs 133 (33.3) 128 (27.4)
Gender
Male 202 (50.6) 234 (50.2)
0.9038
Female 197 (49.4) 232 (49.8)
Education
Illiterate 43 (10.8) 23 (4.9)
<.0001
Primary school 106 (26.6) 81 (17.4)
Junior middle school 124 (31.1) 175 (37.5)
Senior middle school 68 (17.0) 120 (25.8)
College or higher 58 (14.5) 67 (14.4)
Pack years of smoking
Non smokers 179 (44.9) 285 (61.2)
<.0001
< 20 pyrs 39 (9.8) 62 (13.3)
20 – 40 pyrs 64 (16.0) 72 (15.5)
≥ 40 pyrs 117 (29.3) 47 (10.1)
Average income 10 years ago
< 1,000 yuan 104 (26.1) 106 (22.7)
<.00011,000 – 2,500 yuan 236 (59.1) 197 (42.3)
≥ 2,500 yuan 59 (14.8) 163 (35.0)
BMI (kg/m2)
< 18.5 22 (5.8) 9 (2.0)
<.0001
18.5 – 24.9 250 (66.3) 259 (56.3)
25 – 29.9 90 (23.9) 162 (35.2)
≥ 30 15 (4.0) 30 (6.5)
Alcohol drinking
No 298 (74.7) 345 (74.0)
0.8267
Yes 101 (25.3) 121 (26.0)
Tea drinking
No 242 (60.6) 263 (56.5)
<.0001
Previous drinkers 47 (11.8) 15 (3.2)
Current drinkers 110 (27.6) 188 (40.3)
Total 399 466
Adjusted age, gender, education, pack years of smoking, alcohol drinking, tea
drinking and average income 10 years ago.
Significant differences were highlighted in bold.
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tea drinking status. Stratified analyses were conducted
among subgroups with different age, gender, smoking sta-
tus, alcohol and tea drinking status, indoor air pollution
exposure and histo-pathological types of lung cancer.
Multiplicative interactions of TP53 SNPs with some life-
style factors were assessed using ORs for interactions by
including their product terms in the logistic regression
models. Additive interactions were assessed using relative
excess risk due to interaction (RERI), as described previ-
ously [19]. All statistical analyses were performed using
SAS software (version 9.3). Associations were consid-
ered statistically significant if the p-value < 0.05 in the two-
sided test.
Results
Basic characteristics of lung cancer cases and controls
are presented in Table 1. No statistically significant dif-
ferences in age and gender were found between cases
and controls. Controls tended to have higher education
levels, average annual income and body mass index than
cases (p < 0.0001). Lung cancer cases were more likely to
be smokers and had higher pack-years of smoking, but
were less likely to be current tea drinkers (p < 0.0001)
(Table 1).
Table 2 presents the independent associations between
the two TP53 SNPs and lung cancer risk in the total
study population. No significant associations with lung
cancer risk were found for TP53 rs2078486 SNP, despite
a tendency towards an elevated lung cancer risk associ-
ated with the variant genotype. A significantly increased
lung cancer risk was observed among individuals with
the homozygous variant genotype (CC) of TP53 SNP
rs1042522 (adjusted OR: 1.63, 95% CI: 1.10 - 2.41), com-
pared with the homozygous wild type (GG). Adjusted
ORs for rs1042522 were also statistically significant in
the recessive model (adjusted OR: 1.57, 95% CI: 1.11-
2.21), but not in the dominant model. C allele of TP53
SNP rs1042522 was significantly associated with increased
risk of developing lung cancer (adjusted OR: 1.26, 95% CI:
1.04 - 1.53) (Table 2).
Results from the stratified analyses are presented in
Figure 1. Presence of one or both copies of minor allele
(TC or CC) of TP53 rs2078486 SNP was significantly
or borderline significantly associated with elevated
lung cancer risk among older individuals (adjusted
OR: 1.53, 95% CI: 0.97 - 2.41), smokers (adjusted OR:
1.70, 95% CI: 1.08 - 2.67), alcohol drinkers (adjusted
OR: 2.41, 95% CI: 1.25 - 4.65) and individuals with
high indoor air pollution exposure (adjusted OR: 1.51,
95% CI: 1.00-2.30) (Figure 1). Significant multiplica-
tive and additive interactions were found between the
indoor air pollution index and TP53 rs2078486 poly-
morphism (adjusted OR for interaction: 1.89, 95% CI:1.00-3.56, adjusted REPI: 0.90, 95% CI: 0.11-1.70).
There was also some suggestive evidence of multiplicative
interaction between smoking and TP53 rs2078486 poly-
morphism (adjusted OR for interaction: 1.80, 95% CI:
Table 2 Associations of TP53 SNPs with lung cancer risk in Taiyuan lung cancer study in total study population
SNP Genotype
Cases Controls Crude OR
(95% CI)
Adjusted OR*
(95% CI)N % N %
TP53 rs2078486 355 448
CC 186 52.4 250 55.8 1 1
TC 136 38.3 167 37.3 1.10 (0.82, 1.47) 1.20 (0.88, 1.64)
TT 33 9.3 31 6.9 1.43 (0.85, 2.42) 1.30 (0.75, 2.25)
Dominant model Any T vs. CC 169 47.6 198 44.2 1.15 (0.87, 1.52) 1.22 (0.91, 1.63)
Recessive model TT vs. Any C 33 9.3 31 6.9 1.38 (0.83, 2.30) 1.20 (0.70, 2.06)
Allele OR T vs. C 1.15 (0.93, 1.43) 1.17 (0.93, 1.46)
TP53 rs1042522 363 446
GG 118 32.5 161 36.1 1 1
CG 146 40.2 196 43.9 1.02 (0.74, 1.40) 1.07 (0.77, 1.50)
CC 99 27.3 89 20.0 1.52 (1.05, 2.20) 1.63 (1.10, 2.41)
Dominant model Any C vs. GG 245 67.5 285 63.9 1.17 (0.88, 1.57) 1.24 (0.92, 1.69)
Recessive model CC vs. Any G 99 27.3 89 20.0 1.50 (1.08, 2.09) 1.57 (1.11, 2.21)
Allele OR C vs. G 1.21 (1.01, 1.46) 1.26 (1.04, 1.53)
*Adjusted for age, gender, education, pack years of smoking, alcohol drinking, tea drinking and average income 10 years ago.
Significant results were highlighted in bold.
Figure 1 Associations of TP53 rs2078486 with lung cancer among different subgroups with different age, gender, smoking status,
alcohol and tea drinking status, indoor air pollution exposure and histo-pathological types of lung cancer. Adjusted age, gender,
education, pack years of smoking, alcohol drinking, tea drinking and average income 10 years ago. AC: adenocarcinoma, SCC: squamous cell
carcinoma; SmCC: small cell carcinoma. Asterisks indicate significant ORs.
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2.49, 95% CI: -0.03, 5.01) (Table 3).
Elevated risk of lung cancer associated with homozy-
gous variant genotype (CC) of TP53 SNP rs1042522
were observed in each subgroup. No obvious difference
was observed between smokers and nonsmokers (Figure 2).
The variant genotype of TP53 SNP rs1042522 tended to
confer stronger deleterious effect for younger individ-
uals, males, alcohol and tea drinkers, however neither
multiplicative nor additive interactions were observed
between TP53 SNP rs1042522 and any lifestyle factors
on lung cancer risk (Table 3).
Discussion
This case–control study confirmed elevated lung cancer
risk associated with the variant allele (C) of TP53 SNP
rs1042522, and this study is among the first to report a
tendency of increased lung cancer risk associated with
variant genotype of TP53 SNP rs2078486 in an Asian
population. Moreover, we found synergetic effects of
smoking and indoor air pollution exposure with TP53
SNP rs2078486 on lung cancer risk.
Overwhelming evidence suggested that the TP53
tumor suppressor gene is a central regulatory node of
multiple cellular response pathways to endogenous or
exogenous stresses [20]. P53 protein has demonstrated
the capacity to regulate activity of key effectors of cellu-
lar processes, such as DNA repair, cell cycle arrest, sen-
escence, and apoptosis [21,22]. Functional inactivation of
P53 pathways is thought to affect P53 signaling and fur-
ther alter cancer risk [20,23].
TP53 rs2078486 SNP might be a novel TP53 SNP af-
fecting risk of developing lung cancer. One pathway-
based genotyping study conducted among nonsmokers
found statistically significant association between TP53
rs2078486 SNP and lung cancer [10]. In the present
study, we found some suggestive evidence of elevated
lung cancer risk associated with TC or CC genotypes of
TP53 rs2078486 SNP (adjusted OR: 1.22, 95% CI: 0.91 -
1.63) in the overall study participants. Our result was in
similar direction with one population-based case–con-
trol study conducted in Los Angeles (adjusted OR: 1.61,
95% CI: 1.18 – 2.20) [11]. The less significant association
observed in our study might relate to the relatively
smaller sample size. Some other case–control studies
also suggested that variant genotype of TP53 rs2078486
SNP was significantly associated with increased risks of
ovarian cancer and schizophrenia [13,14,24]. Therefore,
this suggests that there might be a functional difference
among different genotypes of TP53 rs2078486 SNP,
which may affect the risk of developing various types of
cancers and other human diseases.
TP53 rs2078486 is located in intron 1 and thus is not
likely to be a direct disease-causing polymorphism.However previous studies suggest that TP53 rs2078486
is in a large linkage disequilibrium block extending from
upstream of exon 1 to the first half of intron 1 [17].
Therefore it is possible that TP53 rs2078486 might be in
linkage disequilibrium with some functional polymor-
phisms, which in turn alter susceptibility to human dis-
eases. Some other intronic variations in TP53 were
reported to affect disease risk previously and the most
widely studied one is TP53 intron 3 duplication poly-
morphism (rs17878362) [5,25]. The underlying mechan-
ism by which TP53 rs2078486 modulates cancer risk is
not fully understood and warrants further investigations.
However prior studies provided some initial evidence
that TP53 rs2078486 is in perfect linkage disequilibrium
with TP53 rs2287498, which is predicted to affect func-
tion at a splice site and TP53 rs2078486 is also in weak
linkage disequilibrium with TP53 rs12951953, which
might affect a transcription factor binding site [13].
Moreover, we found carrying the variant alleles of
TP53 rs2078486 SNP was significantly associated with
elevated lung cancer risk in smokers (adjusted OR: 1.70,
95% CI: 1.08 - 2.67) and individuals with high indoor air
pollution exposure (adjusted OR: 1.51, 95% CI: 1.00-
2.30). Cigarette smoking and air pollution have been
linked with high frequency of TP53 mutations [26-29].
The positive interactions observed between TP53 SNP
rs2078486 with smoking and indoor air pollution expos-
ure in our study might suggest that individuals carrying
the variant genotype of TP53 rs2078486 may have com-
promised P53 function and respond poorly to the ad-
verse effects of smoking and air pollution, thus have an
elevated risk of developing lung cancer. In addition, the
elevated risk associated with high-risk genotypes TP53
rs2078486 SNP was more evident for the small cell carcin-
oma, which has been more strongly linked to cigarette
smoking than the other histo-pathological types of lung
cancer.
Elevated lung cancer risk associated with the variant C
allele of TP53 SNP rs1042522 observed in this study was
consistent with previous studies conducted among the
Asian populations (summarized OR under recessive gen-
etic model: 1.37, 95% CI: 1.20 – 1.57; homozygote com-
parison CC vs. GG: 1.34, 95% CI: 1.16 – 1.56) [8]. In the
present study, we did not find heterogeneity of lung can-
cer risks associated with TP53 SNP rs1042522 in smokers
versus non-smokers, which was also consistent with a
previous meta-analysis [8]. Very few prior studies have
examined if demographic or other lifestyle factors might
modify the association between TP53 SNP rs1042522
and lung cancer. In this study, we did not find statistically
significant interactions between lifestyle factors and TP53
SNP rs1042522 on lung cancer risk.
One major limitation of the present study is that the
relatively small sample size, especially in the stratified
Table 3 Interaction between TP53 SNPs and lifestyle factors in Taiyuan lung cancer study
Cases Controls Crude OR (95% CI) Adjusted OR* (95% CI)
Smoking rs2078486
No CC 95 147 1 1
No TC or TT 70 127 0.85 (0.58, 1.26) 0.93 (0.62, 1.39)
Yes CC 91 103 1.37 (0.93, 2.00) 3.58 (2.02, 6.36)
Yes TC or TT 99 71 2.16 (1.45, 3.22) 6.00 (3.33, 10.81)
OR for interaction 1.85 (1.05, 3.27) 1.80 (0.99, 3.30)
RERI 0.94 (0.14, 1.74) 2.49 (−0.03, 5.01)
Alcohol drinking rs2078486
No CC 147 184 1 1
No TC or TT 124 148 1.05 (0.76, 1.45) 1.06 (0.76, 1.48)
Yes CC 39 66 0.74 (0.47, 1.16) 0.71 (0.42, 1.21)
Yes TC or TT 45 50 1.13 (0.71, 1.78) 1.35 (0.79, 2.30)
OR for interaction 1.45 (0.76, 2.78) 1.79 (0.90, 3.58)
RERI 0.34 (−0.27, 0.95) 0.58 (−0.15, 1.30)
Tea drinking rs2078486
Yes CC 65 107 1 1
Yes TC or TT 75 91 1.36 (0.88, 2.09) 1.44 (0.91, 2.28)
No CC 121 143 1.39 (0.94, 2.06) 1.43 (0.92, 2.22)
No TC or TT 94 107 1.45 (0.96, 2.19) 1.51 (0.94, 2.41)
OR for interaction 0.77 (0.43, 1.35) 0.73 (0.40, 1.32)
RERI −0.30 (−1.08, 0.48) −0.37 (−1.21, 0.48)
Indoor air pollution rs2078486
Low CC 63 124 1 1
Low TC or TT 41 105 0.77 (0.48, 1.23) 0.78 (0.48, 1.28)
High CC 107 122 1.73 (1.16, 2.57) 1.42 (0.92, 2.20)
High TC or TT 104 89 2.30 (1.52, 3.48) 2.11 (1.35, 3.29)
OR for interaction 1.73 (0.94, 3.18) 1.89 (1.00, 3.56)
RERI 0.81 (−0.03, 1.65) 0.90 (0.11, 1.70)
Smoking rs1042522
No GG or CG 120 216 1 1
No CC 48 58 1.49 (0.96, 2.32) 1.59 (1.00, 2.53)
Yes GG or CG 144 141 1.84 (1.33, 2.54) 4.73 (2.78, 8.04)
Yes CC 51 31 2.96 (1.80, 4.88) 8.00 (4.08, 15.71)
OR for interaction 1.08 (0.55, 2.11) 1.07 (0.52, 2.18)
RERI 0.63 (−0.87, 2.14) 2.69 (−1.64, 7.02)
Alcohol drinking rs1042522
No GG or CG 200 263 1 1
No CC 74 69 1.41 (0.97, 2.05) 1.45 (0.98, 2.14)
Yes GG or CG 64 94 0.90 (0.62, 1.29) 0.90 (0.57, 1.41)
Yes CC 25 20 1.64 (0.89, 3.04) 1.86 (0.92, 3.76)
OR for interaction 1.30 (0.61, 2.80) 1.44 (0.63, 3.27)
RERI 0.34 (−0.78, 1.45) 0.52 (−0.82, 1.86)
Tea drinking rs1042522
Yes GG or CG 100 159 1 1
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Table 3 Interaction between TP53 SNPs and lifestyle factors in Taiyuan lung cancer study (Continued)
Yes CC 41 35 1.86 (1.11, 3.12) 2.09 (1.21, 3.61)
No GG or CG 164 198 1.32 (0.95, 1.82) 1.39 (0.95, 2.04)
No CC 58 54 1.71 (1.09, 2.67) 1.81 (1.10, 2.97)
OR for interaction 0.70 (0.36, 1.36) 0.62 (0.31, 1.25)
RERI −0.47 (−1.62, 0.68) −0.67 (−1.99, 0.65)
Indoor air pollution rs1042522
Low GG or CG 73 188 1 1
Low CC 33 41 2.07 (1.22, 3.53) 1.99 (1.14, 3.48)
High GG or CG 159 163 2.51 (1.78, 3.56) 2.04 (1.40, 2.99)
High CC 56 46 3.14 (1.95, 5.04) 2.76 (1.66, 4.58)
OR for interaction 0.60 (0.30, 1.21) 0.68 (0.33, 1.41)
RERI −0.45 (−2.14, 1.24) −0.28 (−1.88, 1.33)
*Adjusted for age, gender, education, pack years of smoking, alcohol drinking, tea drinking and average income 10 years ago.
Significant results were highlighted in bold.
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tions. Large-scale epidemiological studies are needed in
the future to confirm our findings. Second, after conduct-
ing Bonferroni correction for multiple comparisons, no
significant interactions between lifestyle factors and TP53
rs2078486 SNP remained; therefore we cannot exclude
the possibility of spurious associations due to multiple
comparisons. Lastly, recall bias is likely for established orFigure 2 Associations of TP53 rs1042522 with lung cancer among dif
alcohol and tea drinking status, indoor air pollution exposure and his
ORs. AC: adenocarcinoma, SCC: squamous cell carcinoma; SmCC: small cell
alcohol drinking, tea drinking and average income 10 years ago.probable risk factors of lung cancer, such as smoking and
air pollution, in a case–control study. However the asso-
ciation between smoking and lung cancer observed in the
current study is similar to the previous studies conducted
in an Asian population [30]. To minimize the possible re-
call bias on indoor air pollution exposure, we collected
information on several relevant variables, such as cook-
ing, heating and window opening behaviors.ferent subgroups with different age, gender, smoking status,
to-pathological types of lung cancer. Asterisks indicate significant
carcinoma. Adjusted age, gender, education, pack years of smoking,
Li et al. BMC Cancer 2013, 13:607 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/607Conclusions
In conclusion, this case–control study provided prelim-
inary evidence that TP53 rs2078486 SNP is a novel
TP53 SNP that may affect lung cancer risk, especially
among smokers and individuals with high indoor air pol-
lution exposure. There is some further evidence of sig-
nificant interactions between TP53 rs2078486 SNP and
smoking and indoor air pollution exposure on lung can-
cer risk. Further studies with larger sample size and in
different study populations are warranted to confirm our
findings.
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